Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss

Anne-Priscille Trouvin, Vincent GoëbDepartment of Rheumatology, Rouen University Hospital, Rouen, FranceAbstract: Bone remodeling requires a precise balance between resorption and formation. It is a complex process that involves numerous factors: hormones, growth factors, vitamins, and cyto...

Full description

Bibliographic Details
Main Authors: Anne-Priscille Trouvin, Vincent Goëb
Format: Article
Language:English
Published: Dove Medical Press 2010-11-01
Series:Clinical Interventions in Aging
Subjects:
Online Access:https://www.dovepress.com/receptor-activator-of-nuclear-factor-kappab-ligand-and-osteoprotegerin-peer-reviewed-article-CIA
id doaj-1d621b844c5b47c2b20e107b72a9fbe1
record_format Article
spelling doaj-1d621b844c5b47c2b20e107b72a9fbe12020-11-24T23:51:58ZengDove Medical PressClinical Interventions in Aging1178-19982010-11-01Volume 53453545699Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone lossAnne-Priscille TrouvinVincent GoëbAnne-Priscille Trouvin, Vincent GoëbDepartment of Rheumatology, Rouen University Hospital, Rouen, FranceAbstract: Bone remodeling requires a precise balance between resorption and formation. It is a complex process that involves numerous factors: hormones, growth factors, vitamins, and cytokines, and notably osteoprotegerin (OPG) and receptor activator for nuclear factor-κB (RANK) ligand. The signaling pathway OPG/RANK/RANKL is key to regulation for maintaining the balance between the activity of osteoblasts and osteoclasts in order to prevent bone loss and ensure a normal bone turnover. In this review, the RANK/RANKL/OPG pathway is described. The multiple interactions of various factors (hormones, cytokines, growth factors, and vitamins) with the OPG/RANK/RANKL pathway are also commented on. Finally, the effects of denosumab, a human monoclonal antibody that binds to RANKL and thereby inhibits the activation of osteoclasts, and of strontium ranelate are also described. Indeed, these two new drugs afford appreciable assistance in daily care practice, helping to prevent bone loss in patients with osteoporosis.Keywords: osteoprotegerin, OPG, RANK, RANKL, denosumab, strontium ranelate, osteoporosishttps://www.dovepress.com/receptor-activator-of-nuclear-factor-kappab-ligand-and-osteoprotegerin-peer-reviewed-article-CIAOsteoprotegerinRANKRANKLDenosumabStrontium ranelateOsteoporosis
collection DOAJ
language English
format Article
sources DOAJ
author Anne-Priscille Trouvin
Vincent Goëb
spellingShingle Anne-Priscille Trouvin
Vincent Goëb
Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
Clinical Interventions in Aging
Osteoprotegerin
RANK
RANKL
Denosumab
Strontium ranelate
Osteoporosis
author_facet Anne-Priscille Trouvin
Vincent Goëb
author_sort Anne-Priscille Trouvin
title Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
title_short Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
title_full Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
title_fullStr Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
title_full_unstemmed Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
title_sort receptor activator of nuclear factor-κb ligand and osteoprotegerin: maintaining the balance to prevent bone loss
publisher Dove Medical Press
series Clinical Interventions in Aging
issn 1178-1998
publishDate 2010-11-01
description Anne-Priscille Trouvin, Vincent GoëbDepartment of Rheumatology, Rouen University Hospital, Rouen, FranceAbstract: Bone remodeling requires a precise balance between resorption and formation. It is a complex process that involves numerous factors: hormones, growth factors, vitamins, and cytokines, and notably osteoprotegerin (OPG) and receptor activator for nuclear factor-κB (RANK) ligand. The signaling pathway OPG/RANK/RANKL is key to regulation for maintaining the balance between the activity of osteoblasts and osteoclasts in order to prevent bone loss and ensure a normal bone turnover. In this review, the RANK/RANKL/OPG pathway is described. The multiple interactions of various factors (hormones, cytokines, growth factors, and vitamins) with the OPG/RANK/RANKL pathway are also commented on. Finally, the effects of denosumab, a human monoclonal antibody that binds to RANKL and thereby inhibits the activation of osteoclasts, and of strontium ranelate are also described. Indeed, these two new drugs afford appreciable assistance in daily care practice, helping to prevent bone loss in patients with osteoporosis.Keywords: osteoprotegerin, OPG, RANK, RANKL, denosumab, strontium ranelate, osteoporosis
topic Osteoprotegerin
RANK
RANKL
Denosumab
Strontium ranelate
Osteoporosis
url https://www.dovepress.com/receptor-activator-of-nuclear-factor-kappab-ligand-and-osteoprotegerin-peer-reviewed-article-CIA
work_keys_str_mv AT annepriscilletrouvin receptoractivatorofnuclearfactorkappabligandandosteoprotegerinmaintainingthebalancetopreventboneloss
AT vincentgoeumlb receptoractivatorofnuclearfactorkappabligandandosteoprotegerinmaintainingthebalancetopreventboneloss
_version_ 1725475253146091520